BIONTECH SE ($BNTX) posted quarterly earnings results on Monday, November 3rd. The company reported earnings of -$0.12 per share, beating estimates of -$0.17 by $0.05. The company also reported revenue of $1,541,640,601, beating estimates of $979,549,676 by $562,090,925.
You can see Quiver Quantitative's $BNTX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIONTECH SE Hedge Fund Activity
We have seen 118 institutional investors add shares of BIONTECH SE stock to their portfolio, and 139 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 3,512,318 shares (+4076.8%) to their portfolio in Q2 2025, for an estimated $373,956,497
- VIKING GLOBAL INVESTORS LP removed 879,972 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $93,690,618
- DODGE & COX added 877,437 shares (+inf%) to their portfolio in Q2 2025, for an estimated $93,420,717
- FMR LLC added 875,600 shares (+12.0%) to their portfolio in Q2 2025, for an estimated $93,225,132
- MILLENNIUM MANAGEMENT LLC removed 544,970 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $58,022,955
- BANK OF NEW YORK MELLON CORP added 410,351 shares (+58.8%) to their portfolio in Q2 2025, for an estimated $43,690,070
- BLACKROCK, INC. removed 351,912 shares (-21.1%) from their portfolio in Q2 2025, for an estimated $37,468,070
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIONTECH SE Congressional Stock Trading
Members of Congress have traded $BNTX stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $BNTX stock by members of Congress over the last 6 months:
- REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 08/07.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
BIONTECH SE Analyst Ratings
Wall Street analysts have issued reports on $BNTX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 10/10/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/08/2025
- B of A Securities issued a "Buy" rating on 08/05/2025
- Wells Fargo issued a "Overweight" rating on 08/05/2025
- Truist Securities issued a "Buy" rating on 06/03/2025
To track analyst ratings and price targets for BIONTECH SE, check out Quiver Quantitative's $BNTX forecast page.
BIONTECH SE Price Targets
Multiple analysts have issued price targets for $BNTX recently. We have seen 7 analysts offer price targets for $BNTX in the last 6 months, with a median target of $134.0.
Here are some recent targets:
- Jessica Fye from JP Morgan set a target price of $120.0 on 10/23/2025
- Terence Flynn from Morgan Stanley set a target price of $131.0 on 10/10/2025
- Robert Burns from HC Wainwright & Co. set a target price of $136.0 on 09/08/2025
- Tazeen Ahmad from B of A Securities set a target price of $134.0 on 08/05/2025
- Mohit Bansal from Wells Fargo set a target price of $150.0 on 08/05/2025
- Asthika Goonewardene from Truist Securities set a target price of $155.0 on 06/03/2025
- Asad Haider from Goldman Sachs set a target price of $110.0 on 05/29/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
